23rd week of 2012 patent applcation highlights part 54 |
Patent application number | Title | Published |
20120142707 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. | 2012-06-07 |
20120142708 | SUBSTITUTED PYRIDINE UREA COMPOUNDS - The present disclosure provides pyridine urea compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): | 2012-06-07 |
20120142709 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS - The present disclosure provides pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): | 2012-06-07 |
20120142710 | Ketolide Compounds Having Antimicrobial Activity - The invention relates to ketolide compound of Formula-I and the pharmaceutically acceptable salts thereof having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compound of invention. | 2012-06-07 |
20120142711 | ACID-LABILE TRIGGER UNITS - The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound. | 2012-06-07 |
20120142712 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS - The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof. | 2012-06-07 |
20120142713 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE - The present invention relates to the solid state of 6-(1H-imidazol-1-yl)-2-phenylquinazoline (I) and therefore to novel crystalline forms of the base and of pharmaceutically acceptable salts and solvates thereof, and also to methods for preparing them, to the respective pharmaceutical formulations and to their therapeutic use. Compound (I) may be obtained as the free base in five different crystalline forms, three polymorphic forms and two hydrates. Some pharmaceutically acceptable salts of (I) that have physicochemical characteristics acceptable for pharmaceutical development were obtained, and the respective polymorphic forms and/or hydrates were characterized. | 2012-06-07 |
20120142714 | BICYCLIC COMPOUND - The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. | 2012-06-07 |
20120142715 | POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-BENZYL)PYRIMIDIN-5-YL] - Provided is a crystalline form of the ethylenediamine salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid, processes for its preparation, pharmaceutical compositions comprising it, and methods of its use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease. | 2012-06-07 |
20120142716 | 4-PYRIMIDINESULFAMIDE DERIVATIVE - The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound. | 2012-06-07 |
20120142717 | COMPOUNDS - The present invention relates to novel compounds that inhibit Lp-PLA | 2012-06-07 |
20120142719 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof - The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2012-06-07 |
20120142720 | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof - The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2012-06-07 |
20120142721 | SMALL MOLECULE INHIBITORS OF POLYNUCLEOTIDE KINASE/PHOSPHATASE, POLY(ADP-RIBOSE) POLYMERASE AND USES THEREOF - The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions. | 2012-06-07 |
20120142722 | CONJUGATES OF CYTOTOXIC DRUGS - Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. In another aspect of the invention there is provided a conjugate, comprising a cytotoxic agent and a modulating moiety, the modulating moiety serving to target apoptotic cells. | 2012-06-07 |
20120142723 | ACE2 ACTIVATOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury. | 2012-06-07 |
20120142724 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS - The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer. | 2012-06-07 |
20120142725 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent - The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided. | 2012-06-07 |
20120142726 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4-DIHYDROISOQUINOLIN-2(1H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY - The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative. | 2012-06-07 |
20120142727 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE - [Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT | 2012-06-07 |
20120142728 | CHEMICAL COMPOUND AND ITS USE - The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis. | 2012-06-07 |
20120142729 | KAT ll INHIBITORS - The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans. | 2012-06-07 |
20120142730 | USE OF LAQUINIMOD FOR REDUCING FATIGUE, IMPROVING FUNCTIONAL STATUS, AND IMPROVING QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS - The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis human patient, comprising orally administering to the human patient laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a method for providing neuroprotection to a human subject, the method comprising orally administering to the human subject laquinimod or a pharmaceutically acceptable salt thereof. | 2012-06-07 |
20120142731 | METHODS OF INHIBITING VIRAL INFECTION - Compounds, pharmaceutical compositions and methods of inhibiting viral infection in a mammal in need of same, are provided, which employ compounds of the formula | 2012-06-07 |
20120142732 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula IA or IB: | 2012-06-07 |
20120142733 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2012-06-07 |
20120142734 | METHODS FOR TREATING TUMORS WITH THALIDOMIDE - The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally. | 2012-06-07 |
20120142735 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES - The present invention extends to a compound of formula I: | 2012-06-07 |
20120142736 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-06-07 |
20120142737 | PHARMACEUTICAL COMPOSITIONS OF A NON-ENTERIC COATED PROTON PUMP INHIBITOR WITH A CARBONATE SALT AND BICARBONATE SALT COMBINATION - A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate. | 2012-06-07 |
20120142738 | Pharmaceutical composition for treating dermatological autoimmune diseases - There is proposed a pharmaceutical composition for treating dermatological autoimmune diseases, comprising a proton pump inhibitor. | 2012-06-07 |
20120142739 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-06-07 |
20120142740 | NOVEL ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-06-07 |
20120142741 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER - This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I is as follows: | 2012-06-07 |
20120142742 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 2012-06-07 |
20120142743 | PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORMS OF FLUPIRTINE MALEATE - New polymorphic forms of flupirtine maleate are described. | 2012-06-07 |
20120142744 | NOVEL COMPLEXES OF FATTY ACID ESTERS OF POLYHYDROXYALKANES AND PYRIDINE CARBOXY DERIVATIVES - The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivates such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed herein. | 2012-06-07 |
20120142745 | NOVEL PHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel phenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-06-07 |
20120142746 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2012-06-07 |
20120142747 | COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE TO A TARGET TISSUE SITE - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer. | 2012-06-07 |
20120142748 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION - The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor. | 2012-06-07 |
20120142749 | SOLID SALT FORMS OF A PYRROLE SUBSTITUTED 2-INDOLINONE - The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1, 2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pirrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders. | 2012-06-07 |
20120142750 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS - The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof. | 2012-06-07 |
20120142751 | METHODS FOR THE PRODUCTION OF BILIVERDIN - The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially | 2012-06-07 |
20120142752 | HIV PROTEASE INHIBITORS - Compounds of Formula (I) are disclosed; wherein X | 2012-06-07 |
20120142753 | DIAGNOSIS AND TREATMENT OF ADRENOCORTICAL TUMORS USING HUMAN MICRORNA-483 - Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include detecting expression of at least one microRNA (miR) gene product, such as miR-100, miR-125b, miR-195, miR-483-3p, miR-483-5p and IGF2 mRNA in a sample obtained from the subject with an adrenocortical tumor and comparing expression of at least one of these miR gene products and IGF2 mRNA in the sample obtained from the subject to a control. Altered expression of at least one of the miR gene products and IGF2 mRNA, such as a decrease in miR-100, miR-125b or miR-195 or an increase in miR-483-3p, miR-483-5p, and an increase in IGF2 mRNA, in the sample obtained from the subject compared to the control indicates a malignant adrenocortical tumor. | 2012-06-07 |
20120142754 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION - Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMP1 and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding TIMP1 and TIMP2, for example, the gene encoding human TIMP1 and TIMP2. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with TIMP1 and TIMP2 including fibrotic diseases and disorders including liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis. | 2012-06-07 |
20120142755 | COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION - The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. | 2012-06-07 |
20120142756 | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES - Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed. | 2012-06-07 |
20120142757 | RNAi Modulation of AHA and Therapeutic Uses Thereof - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell. | 2012-06-07 |
20120142758 | TREATMENT OF DOWN SYNDROME GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A DOWN SYNDROME GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes. | 2012-06-07 |
20120142759 | SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH. | 2012-06-07 |
20120142760 | COMPOSITIONS AND METHODS FOR REGULATED PROTEIN EXPRESSION IN GUT - The invention provides compositions and methods useful for treating disorders treatable by producing a protein in a regulatable manner in a mucosal cell or tissue of an animal. The treatment methods include in vivo and ex vivo methods, including transplanting in vitro transformed cells that secrete the protein into a mammalian subject. | 2012-06-07 |
20120142761 | OLIGONUCLEOTIDES OR THEIR FUNCTIONAL HOMOLOGUES, A COMPOSITION COMPRISING THE SAME AND A METHOD OF TREATING B CELL NEOPLASM - The invention provides nine oligonuleotides with sequences of SEQ ID NO:1-9 or their functional homologues or a composition comprising the same and a method for treating B cell neoplasm by using the oligonuleotides or their functional homologues or the composition comprising the oligonuleotides. The oligonuleotides induce the apoptosis of B cell neoplastic cells, up-regulate CD40 on B cell neoplastic cells and stimulate the production of IL-10 from B cell neoplastic cells. | 2012-06-07 |
20120142762 | Method for Preventing and Treating Cardiovascular Diseases with BRCA1 - Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases. | 2012-06-07 |
20120142763 | NUCLEIC ACID DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF - This disclosure relates to nucleic acid constructs modified to have a reduced net anionic charge. The constructs comprise phosphotriester and/or phosphothioate protecting groups. The disclosure also provides methods of making and using such constructs. | 2012-06-07 |
20120142764 | Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes - The present invention relates to one multi-cistronic shRNA for suppressing single or multiple target genes, and more particularly, to a multi-cistronic shRNA expression cassette, an expression vector comprising the multi-cistronic shRNA expression cassette, cells transduced with the multi-cistronic shRNA expression vector, a composite of the expression vector and a carrier, a method for suppressing various target genes, and a composition for suppressing target genes comprising the expression vector. | 2012-06-07 |
20120142765 | Sphingosine-bound siRNA - The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression. | 2012-06-07 |
20120142766 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES - The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 2012-06-07 |
20120142767 | PINE PCO ESTER COSMETIC COMPOSITION - The invention relates to a cosmetic composition for repairing and optionally preventing the effects of skin ageing, based on an extract of | 2012-06-07 |
20120142768 | FORMULATIONS INCLUDING AMIODARONE AND SALTS THEREOF AND METHODS OF THEIR MANUFACTURE AND USE - The invention encompasses ready to administer liquid formulations including amiodarone and a substituted cyclodextrin. The invention also encompasses methods of making the liquid formulations to provide acceptable concentrations of amiodarone suitable for parenteral administration. The liquid formulations of the invention are formulations included, for example, in a ready to use intravenous bag, bottle or syringe. | 2012-06-07 |
20120142769 | METHODS FOR TREATING OR PREVENTING FATIGUE - The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments. | 2012-06-07 |
20120142770 | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELATABLE METAL COMPOUNDS, AND METAL-HDAC INHIBITOR CHELATE COMPLEXES - The present invention provides pharmaceutical compositions of an HDAC inhibitor and a chelatable metal compound. In one embodiment, the invention provides a method of treating cancer and alleviating the side effects of the HDAC inhibitor by administering the pharmaceutical composition. In another embodiment, the present invention also provides pharmaceutical compositions of metal HDAC inhibitor chelate complexes. In another embodiment, the invention provides methods of treating cancer by administering the pharmaceutical compositions. The invention provides crystalline compositions of metal HDAC inhibitor chelate complexes and methods of producing same. | 2012-06-07 |
20120142771 | BIPHENYLACETAMIDE DERIVATIVE - The present invention provides a compound of formula (I) or a salt thereof, wherein R | 2012-06-07 |
20120142772 | Benzo Lipoxin Analogues - Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation. | 2012-06-07 |
20120142773 | USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), | 2012-06-07 |
20120142774 | EMULSIFYING PREPARATION - An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble component, (B) an aqueous phase component containing a polyol, and (C) an emulsifier containing polyglycerol fatty acid monoester having an average degree of polymerization of not less than 10, and having an HLB value of not less than 14 and not more than 18 or showing a transmittance of 1 wt % aqueous solution at 600 nm of not less than 80%. | 2012-06-07 |
20120142775 | TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 2012-06-07 |
20120142776 | METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY - Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition. | 2012-06-07 |
20120142777 | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN ALPHA-AMINOAMIDE AND ITS ANALGESIC USE - There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an α-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed. | 2012-06-07 |
20120142778 | MICROBIOLOGICAL METHOD FOR SYNTHESIZING CINNAMOYL AMIDE DERIVATIVES OF AMINO ACIDS - Method for the microbiological production of cinnamoyl amide derivatives of amino acids, certain products that result therefrom and uses thereof, especially as antioxidants. | 2012-06-07 |
20120142779 | STABLE INJECTABLE COMPOSITIONS - This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine. | 2012-06-07 |
20120142780 | USE OF 2,5-DIHYDROXYBENZENESULFONIC ACID IN THE MANUFACTURING OF MEDICINES, APPLICABLE TO THE TREATMENT OF ANGIODEPENDENT DISEASES - The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques. | 2012-06-07 |
20120142781 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 2012-06-07 |
20120142782 | ENHANCED CIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. | 2012-06-07 |
20120142783 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. | 2012-06-07 |
20120142784 | LYSINE-SPECIFIC DEMETHYLASE 1(LSD1) IS A BIOMARKER FOR BREAST CANCER - The present invention relates to novel biomarker for breast cancer, namely LSD1 and its application in inter alia the diagnosis of breast cancer. Furthermore, the present invention discloses a method of determining the LSD1 protein amount and the effect of LSD1 inhibitors on cancer cells selected from breast cancer, lung carcinoma and sarcoma. | 2012-06-07 |
20120142785 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Alzheimer's disease is treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. | 2012-06-07 |
20120142786 | OREGANO EXTRACT FOR ALERTNESS - extract can act as a stimulant, yet it does not interfere with sleep patterns or induce nervousness the way many stimulants such as caffeine can. It also has the benefits of promoting improved vigilance, improving attention and ability to focus on a task, and improving general alertness. | 2012-06-07 |
20120142787 | ALDEHYDE-FUNCTIONALIZED POLYSACCHARIDES - Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions. | 2012-06-07 |
20120142788 | COSMETIC PREPARATION CONTAINING ACYL ARGINATES - Cosmetic or dermatological emulsions with a content of one or more acyl arginates of the formula, wherein R can have values from 5 through 17 and preferably represents an unbranched alkyl chain of 11 C atoms (=lauroyl arginate). | 2012-06-07 |
20120142789 | Catalytic Reaction Module - A catalytic reaction module for performing am endothermic reaction, such as steam reforming, including separator blocks. Each reactor defining a multiplicity of first and second flow channels arranged alternately within the block to ensure thermal contact between the first and second flow channels. The reactor blocks may be arranged and connected for series flow of a combustible gas mixture in the first flow channels. The reactor blocks may be arranged and connected for a gas mixture to undergo endothermic reaction in the second flow channels. Catalyst elements are provided within the flow channels and the catalyst may vary between the blocks or within a block. The catalyst may vary in chemical composition, in catalyst loading, or in active catalyst material. | 2012-06-07 |
20120142790 | POLY(ARYLENE ETHER) COPOLYMER HAVING CATION-EXCHANGE GROUP, PROCESS OF MANUFACTURING THE SAME, AND USE THEREOF - The present invention relates to a poly(arylene ether) copolymer having a cation exchange group, a method for manufacturing the same, and use thereof. The poly(arylene ether) copolymer having the cation exchange group according to the present invention has excellent physical characteristics, ion exchanging capacity, metal ion adsorption capacity and a processability, and thus can be molded in various shapes and can be extensively applied to various fields such as recovering of organic metal, air purification, catalysts, water treatment, medical fields and separating of proteins. | 2012-06-07 |
20120142791 | Solid Electrolyte Membrane for Fuel Cell and Process for Producing Same - Disclosed are a solid electrolyte membrane for fuel cells, which is characterized by that there has been used a silicone resin obtained by subjecting a methide series siloxane compound having a specific, strong acid bis(perfluoroalkanesulfonyl)methide moiety, a specific polysiloxane compound, and a specific silane compound to a cross-linking reaction, and its production process. This membrane has heat resistance, is superior in chemical stability, has a good proton conductivity even under a low water content condition, and has a low methanol permeability. | 2012-06-07 |
20120142792 | REMOVAL OF LIGHT FLUOROALKANES FROM HYDROCARBON STREAMS - The removal of fluoroalkanes from fluoroalkane-containing hydrocarbon streams, preferably C | 2012-06-07 |
20120142793 | SILSESQUIOXANE PHOTOINITIATORS - Photoinitiator compounds comprising both a photoactive moiety and an amine functionality, bonded to a polyhedral oligomeric silsesquioxane, which photoinitiator is represented by formula (1) or (1′) wherein n is 2m; m is an integer of 2 to 30; the sum of n′+a is an integer 4-60; n′ is an even-numbered integer; a is an even- or uneven-numbered integer; and for example different A C | 2012-06-07 |
20120142794 | FOAM WITH FILLING - The present invention relates to open-cell foams filled with polyamide and also to a production process therefor. | 2012-06-07 |
20120142795 | HIERARCHICAL THERMOPLASTIC SURFACE TEXTURES FORMED BY PHASE TRANSFORMATION AND METHODS OF MAKING - Method for treating thermoplastic to make a surface thereof superhydrophobic. The method includes exposing the thermoplastic to a specific solvent for a selected time period. It is preferred that the treatment time be in the range of one minute to approximately five hours and more preferably in the range of one minute to 15 minutes. Thermoplastics and solvents having a similar solubility parameter interact with one another to form hydrophobic hierarchical surfaces. | 2012-06-07 |
20120142796 | PROCESSABILITY IMPROVER FOR FOAM MOLDING AND VINYL CHLORIDE RESIN COMPOSITION CONTAINING SAME - An object of the present invention is to provide a foaming vinyl chloride resin composition having excellent foaming properties and providing a foam molded product with an excellent appearance by enhancing the melt strength of the vinyl chloride resin composition. A processability improver for foam molding according to the present invention includes a (meth)acrylic polymer powder with a weight average molecular weight of 2,000,000 to 7,000,000, wherein the (meth)acrylic polymer powder includes 1 to 20% by weight of a (meth)acrylic polymer (A) with a weight average molecular weight of 10,000 to 300,000, and 80 to 99% by weight of a (meth)acrylic polymer (B) with a weight average molecular weight of 2,000,000 to 7,000,000. | 2012-06-07 |
20120142797 | PROCESS FOR THE PREPARATION OF EXPANDABLE POLYSTYRENE BY CONTINUOUS INJECTION OF A LIQUID ORGANIC PEROXIDE - A process for the preparation of expandable polystyrene including the following steps: i°) heating an aqueous suspension including styrene monomer and at least one organic peroxide initiator of formula (I) 1-alkoxy- | 2012-06-07 |
20120142798 | PROCESS FOR TEXTURING MATERIALS - Provided are methods for making textured implantable materials made from two part RTV silicone foams and having a desired color or tone without the need for dyes or colorants. | 2012-06-07 |
20120142799 | POLYESTER POLYOLS BASED ON AROMATIC DICARBOXYLIC ACIDS - The present invention relates to polyester polyols based on aromatic dicarboxylic acids and their use for producing rigid polyurethane foams. | 2012-06-07 |
20120142800 | POROUS GELS BASED ON AROMATIC AND CYCLOALIPHATIC AMINES - The invention relates to a porous gel comprising the following components, in reacted form:
| 2012-06-07 |
20120142801 | CORE FOAMS OF POLYURETHANE FOR PRODUCTION OF WINGS AND BLADES FOR WIND POWER SYSTEMS IN PARTICULAR - A reinforced polyurethane foam obtained by (1) mixing polyisocyanates (a) with compounds having isocyanate-reactive groups (b), a blowing agent containing water (c), and optionally a catalyst (d) and further additives (e) to form a reaction mixture, and (2) curing the reaction mixture, where the reaction mixture to be cured contains hollow microspheres and/or is applied to a porous reinforcing agent (f) capable of forming two-dimensional or three-dimensional networks in the polyurethane foam. The compounds having isocyanate-reactive groups (b) include polyetherols (b1), polyesterols (b2), chain extenders (b3) and optionally crosslinkers (b4) and aromatic polyether diols (b5), and the sum of (b2), (b3) and (b5) is at least 50% by weight of component (b). A process for producing such reinforced polyurethane foams and their use as reinforcing foams for load-bearing, stiff areal elements, in the interior of wings or blades, and also as insulation material for liquefied natural gas tanks. | 2012-06-07 |
20120142802 | MELAMINE RESIN FOAMS WITH NANOPOROUS FILLERS - The invention relates to open-cell melamine resin foams filled with nanoporous particles, especially aerogels or aerosils, and production and use of said foams. | 2012-06-07 |
20120142803 | METHOD FOR CURING A SILICONE RESIN COMPOSITION - A method for curing a silicone resin composition with heat, wherein the silicone resin composition comprises (A) an organopolysiloxane having at least two alkenyl groups per molecule, (B) an organohydrogenpolysiloxnae having, per molecule, at least two hydrogen atoms each bonded to a silicon atom, and (C) a photoactive catalyst, wherein the method is characterized by comprising a step of irradiating the silicone resin composition with light before a step of heating, the light has a maximum peak of irradiance in a region of wavelengths of 300 to 400 nm and an irradiance of light of wavelength shorter than 300 nm is 5% or less of the irradiance at the maximum peak. | 2012-06-07 |
20120142804 | Radical Polymerization Inhibitors for Light-Curable Dental Materials - A light-curable dental material is provided, comprising a polymerizable compound having at least one ethylenically unsaturated bond, a photopolymerization initiator for polymerizing said polymerizable compound, and a 1,3-dipolar compound as a polymerization inhibitor. | 2012-06-07 |
20120142805 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES - The invention pertains to an oligomer or polymer substituted by one or more bisacylphosphine oxide moieties, characterized in that said bisacylphosphine oxide moiety is linked via the phosphorous atom, optionally via a spacer group, to the oligomer or polymer backbone; as well as to specifically functionalized bisacylphosphine oxides, suitable to prepare said polymers or oligomers. | 2012-06-07 |
20120142806 | PHOTOSENSITIVE COMPOSITION - Provided is a photosensitive composition which can be cured with low energy consumption, even when a substance (such as a colorant) that attenuates or shades an illumination light is contained in a high concentration or even when the photosensitive composition is in the form of a thick film. Specifically provided is a photosensitive composition which comprises the following four components: (1) a radical initiator (A); (2) an acid generator (B) or a base generator (C); (3) a polymerizable substance (D); and (4) a colorant (E), a metal oxide powder (F), or a metal powder (G). Further, the photosensitive composition is characterized in that the radical initiator (A), the acid generator (B), and/or the base generator (C) generates an active species (H) through irradiation with an active ray of light; the active species (H) reacts the radical initiator (A), the acid generator (B), or the base generator (C) to form another species (I); and thus the polymerization of the polymerizable substance (D) by means of the active species (I) proceeds, said active species (H) or (I) being an acid or a base. | 2012-06-07 |
20120142807 | EPOXY-CONTAINING DENTAL COMPOSITION CURABLE BY MULTIPLE POLYMERIZATION MECHANISMS - Polymerizable compositions are provided that contain an epoxy compound and a polymerizable, ethylenically-unsaturated resin having an acid functional group where the epoxy compound is polymerized by cationic polymerization initiated by the acid functional group and the polymerizable, ethylenically-unsaturated resin is polymerized by free-radical polymerization. To that end, a two-part polymerizable composition is provided that has a first part containing the epoxy compound; and a second part containing the polymerizable, ethylenically-unsaturated resin having an acid functional group. The first part and/or the second part further contain a radical initiator effective to initiate either self-curing or light-curing by free-radical polymerization. | 2012-06-07 |